Through targeted modification of adenosine A2A receptors expressed in the basal ganglia, istradefylline counteracts the common side effects of levodopa treatment such as wearing off, dyskinesias, and on-off fluctuations with potential for additional neuroprotective effects [50,51]. Here, ADORA2A is linked to drug-induced dyskinesia.